Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing

被引：0
|
作者：
Kavanaugh, Arthur [1 ]
McInnes, Iain B. [2 ]
Mease, Philip J. [3 ]
Hall, Stephan [4 ]
Chinoy, Hector [5 ]
Kivitz, Alan J. [6 ]
Patekar, Manmath [7 ]
Wang, Zailong [8 ]
Mpofu, Shephard [9 ]
机构：
[1] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[2] Univ Glasgow, Immunol Infect & Inflammat, Glasgow, Lanark, Scotland
[3] Swedish Med Ctr, Rheumatol Res, Seattle, WA USA
[4] Monash Univ, Melbourne, Vic 3004, Australia
[5] Univ Manchester, Manchester, Lancs, England
[6] Altoona Ctr Clin Res, Duncansville, PA USA
[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2146
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SECUKINUMAB, A MONOCLONAL ANTIBODY TO INTERLEUKIN-17A, SIGNIFICANTLY IMPROVES SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF A 52-WEEK PHASE 3 RANDOMIZED PLACEBO-CONTROLLED TRIAL WITH INTRAVENOUS LOADING AND SUBCUTANEOUS MAINTENANCE DOSING
    Collins, A.
    Baeten, D.
    Braun, J.
    Baraliakos, X.
    Sieper, J.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Porter, B.
    Martin, R.
    Mpofu, S.
    Richards, H.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 41 - 41
  • [32] SECUKINUMAB SIGNFICANTLY IMPROVES THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN PATIENTS PREVIOUSLY EXPOSED TO ANTI-TUMOUR NECROSIS FACTOR THERAPY AND ANTI-TUMOUR NECROSIS FACTOR-NAIVE PATIENTS: 52 WEEK RESULTS FROM THE PHASE III FUTURE 2 TRIAL
    McInnes, Iain
    Chinoy, Hector
    Kavanaugh, Arthur
    Wang, Zailong
    Mpofu, Shephard
    RHEUMATOLOGY, 2016, 55 : 141 - 141
  • [33] Efficacy and Safety of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
    Aletaha, Daniel
    Bingham, Clifton, III
    Tanaka, Yoshiya
    Agarwal, Prasheen
    Kurrasch, Regina
    Tak, Paul-Peter
    Popik, Sharon
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [34] EFFICACY OF GOLIMUMAB, A HUMAN ANTI-TNFα ANTIBODY, BY BASELINE CRP LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
    Emery, Paul
    Genovese, Mark C.
    Fleischmann, Roy M.
    Matteson, Eric L.
    Hsia, Elizabeth C.
    Xu, Stephen
    Doyle, Mittie K.
    Rahman, Mahboob U.
    RHEUMATOLOGY, 2010, 49 : I101 - I101
  • [35] Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing.
    Baeten, Dominique L.
    Braun, Juergen
    Baraliakos, Xenofon
    Sieper, Joachim
    Dougados, Maxime
    Emery, Paul
    Deodhar, Atul A.
    Porter, Brian
    Martin, Ruvie
    Mpofu, Shephard
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S360 - S360
  • [36] Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
    Mease, Philip J.
    Chohan, Saima
    Fructuoso, Ferran J. Garcia
    Luggen, Michael E.
    Rahman, Proton
    Raychaudhuri, Siba P.
    Chou, Richard C.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Gottlieb, Alice
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (09) : 1147 - 1157
  • [37] INTRAVENOUS LOADING AND SUBCUTANEOUS MAINTENANCE WITH SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT IN MULTIPLE MEASURES OF DISEASE ACTIVITY IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK DATA FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 MEASURE 1 STUDY
    Wei, J. C. C.
    Baeten, D. L.
    Geusens, P.
    Porter, B.
    Martin, R.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1146 - 1147
  • [38] Bimekizumab Treatment in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
    Ritchlin, Christopher
    Coates, Laura
    McInnes, Iain
    Mease, Philip J.
    Merola, Joseph
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vish
    Coarse, Jason
    Landewe, Robert
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4533 - 4536
  • [39] Vedolizumab Induction Therapy for Patients With Crohn's Disease and Prior Anti-TNF Antagonist Failure: A Randomized, Placebo-controlled, Double-blind, Multicenter Trial
    Sands, Bruce
    Feagan, Brian
    Rutgeerts, Paul
    Colombel, Jean-Frederic
    Sandborn, William
    Sy, Richmond
    D'Haens, Geert
    Ben-Horin, Shomron
    Xu, Jing
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    Hanauer, Stephen
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S24 - S25
  • [40] Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.
    McInnes, Iain B.
    Mease, Philip J.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Rahman, Proton
    van der Heijde, Desiree
    Landewe, Robert B. M.
    Conaghan, Philip G.
    Richards, Hanno
    Ligozio, Gregory
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (12) : 3529 - 3529
12345